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The cause of mental retardation in one-third to one-half of all affected individuals is unknown.Microscopicallydetectable
chromosomal abnormalities are the most frequently recognized cause, but gain or loss of chromosomal segments that
are too small to be seen by conventional cytogenetic analysis has been found to be another important cause. Array-based
methods offer a practical means of performing a high-resolution survey of the entire genome for submicroscopic copy-
number variants.We studied 100 childrenwith idiopathicmental retardation andnormal results of standardchromosomal
analysis, by use of whole-genome sampling analysis with Affymetrix GeneChip Human Mapping 100K arrays. We found
de novo deletions as small as 178 kb in eight cases, de novo duplications as small as 1.1 Mb in two cases, and unsuspected
mosaic trisomy 9 in another case. This technology can detect at least twice as many potentially pathogenic de novo
copy-number variants as conventional cytogenetic analysis can in people with mental retardation.
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Mental retardation (MR) produces life-long disability, and
its burden on affected families and society is enormous.
Moderate-to-severe MR, which occurs in ∼1% of the
population,1,2 is etiologically heterogeneous. Chromoso-
mal abnormalities are the most common recognized
cause, accounting for ∼10% of MR in most case series,3,4
but no etiology is recognized in at least one-third to one-
half of all affected individuals. Accurate genetic counsel-
ing and prenatal diagnosis are not available for families
of children with MR in whom no etiology is recognized.
These children often endure a “diagnostic odyssey” of re-
peated testing for many different conditions, in an at-
tempt to ﬁnd the cause.
Chromosomal abnormalities are usually identiﬁed by
cytogenetic analysis, a microscopic method of detecting
gross gain, loss, or rearrangement of genetic material in
dividing cells. There have been evolutionary improve-
ments in karyotyping since its introduction as a routine
clinical service 140 years ago,5–7 but cytogenetic analysis
has been resistant to quantum improvements and to au-
tomation, because of the requirement for tissue culture
and for highly skilled technologists to analyze the micro-
scopic images. Standard cytogenetic analysis has the ad-
vantage of surveying the entire genome for gain or loss
of genetic material in a single test, but it cannot detect
imbalances of genetic segments !5–10 Mb.
Over the past several years, constitutional gain or loss
of genomic segments containing only 1–5 Mb of DNA has
been found to be another important cause of MR.8 These
submicroscopic chromosomal alterations are usually di-
agnosed by locus-speciﬁc FISH,9 a test that provides much
higher resolution than that of conventional cytogenetic
analysis. However, locus-speciﬁc FISH is a labor-intensive
microscopic technique that uses probes speciﬁcally de-
signed for each locus (or for the relatively small number
of loci) tested. FISH is, therefore, not suitable for ge-
nomewide searches for DNA copy-number changes. Better
methods are needed to perform genomewide surveys for
submicroscopic genomic copy-number changes in indi-
viduals with MR.
Array-based methods can provide high-resolution sur-
veys of the entire genome for submicroscopic copy-num-
ber variants (CNVs). A few small studies using these meth-
ods have found apparently pathogenic CNVs among
children with MR who had normal conventional cyto-
genetic analyses.10–17 These studies were done with arrays
made with large-insert clones, usually BACs. The patho-
genic submicroscopic deletions and duplications detected
in these studies range in size from 0.5 to 15 Mb. However,
smaller deletions and duplications can also cause MR.18–24
The ideal technique would, therefore, identify CNVs with
an even greater genomewide resolution.
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Figure 1. Flow diagram showing algorithm used for detection of
CNVs by use of WGSA with Mapping 100K arrays.
Table 1. CNV Detection with CNAG in Trios
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
High-density whole-genome SNP arrays have been
widely used for genotyping25 and can also be used to mea-
sure genomic copy number.26,27 Recent studies have shown
that whole-genome sampling analysis (WGSA)28 with Af-
fymetrix GeneChip Human Mapping 100K array sets can
identify submicroscopic CNVs as well as uniparental di-
somy (UPD) without copy-number change.29–31We studied
100 children with idiopathic MR and their parents, using
WGSA with Mapping 100K arrays to look for potentially
pathogenic submicroscopic genomic changes.
Methods
Patients and Families
We studied 100 children with idiopathic MR and both of
their unaffected parents, eight unaffected siblings within
these families (as negative controls), and eight trios in
which the child hadMR and a previously recognized chro-
mosomal abnormality or UPD (as positive controls). Each
of the children with idiopathic MR was assessed by a clin-
ical geneticist who was unable to determine the cause of
the child’s MR despite thorough clinical evaluation and
clinical testing that included routine karyotyping with at
least 450-band resolution. The children were selected be-
cause they had moderate-to-severe MR or developmental
delay with at least one of the following additional clinical
features: one major malformation, microcephaly, abnor-
mal growth, or multiple minor anomalies. Informed con-
sent was obtained from each family, and assent was also
obtained from the child, if possible. The study was ap-
proved by the University of British Columbia Clinical Re-
search Ethics Board.
DNA Preparation
DNA was extracted from whole blood by use of a Gentra
Puregene DNA Puriﬁcation Kit by following the manufac-
turer’s instructions. The DNA was precipitated in 70% al-
cohol, was resuspended in hydration solution, and was
stored at 4ºC.
Hybridization to Mapping 100K Arrays
Genomic DNA sample quality was assessed by electro-
phoresis in a 0.7% agarose gel, followed by SYBR Green
staining and visualization by use of a Typhoon 9400 var-
iablemode imager. DNA concentrationwasmeasuredwith
a Bio-Tek PowerWave X spectrophotometer. A sample of
500 ng of DNAwas processed according to the instructions
provided in the Affymetrix GeneChip Human Mapping
100K Assay Manual.31 In brief, 250 ng of high-quality
genomic DNA was digested with XbaI or HindIII and was
ligated to XbaI or HindIII adaptors. Adaptor-ligated re-
striction fragments were ampliﬁed by PCR, and the
puriﬁed PCR products were quantiﬁed with a Bio-Tek
PowerWave X spectrophotometer. Random fragmentation
and labeling were performed as described elsewhere.31
Samples were hybridized to GeneChip Human Mapping
50K Xba240 or Hind240 arrays in an Affymetrix Hybrid-
ization Oven 640. Washes and staining of the arrays were
performed with an Affymetrix Fluidics Station 450, and
images were obtained using an Affymetrix GeneChip
Scanner 3000.
The protocol used to identify CNVs is summarized in
ﬁgure 1. Initial analysis and quality assessment of the array
data were performed using GeneChip DNA Analysis Soft-
ware (GDAS) version 3.0.
Copy-Number Analysis of Autosomes with CNAG
Detection of CNVs within trios consisting of an affected
child and both unaffected parents was performed using
Copy Number Analyser for GeneChip (CNAG)32 version
1.0. For each trio, three comparisons of SNP copy number
were made: child versus father (as reference), child versus
mother (as reference), and father versus mother (as ref-
erence). Regions of copy-number gain or loss in these com-
parisons were determined using the hiddenMarkovmodel
output of CNAG. De novo and inherited deletions and
duplications in the children were called using the rules
described in table 1.
Copy-Number Analysis of Autosomes with dChip
An analysis complementary to that described above was
performed using a reference set that included all 216 un-
affected parents in this study. SNP copy number was as-
sessed in each affected child and each unaffected parent
in comparison with this large reference set, by use of DNA-
Chip Analyzer (dChip) software (version release Novem-
ber 17, 2005).33 Regions of copy-number gain or loss were
detected using the hiddenMarkovmodel output of dChip.
De novo and inherited deletions and duplications in the
children were called as described in table 2.
Calculation of t Statistics for Identiﬁcation of the Most
Signiﬁcant Aberrations
The software packages used to detect CNVs each employ
a different algorithm to identify genomic regions of ar-
bitrary size that have higher or lower copy number than
adjacent regions. To compare CNV calls made by different
packages and to identify the calls that were most likely to
be biologically meaningful, we calculated t statistics and
the corresponding P values for mean sample versus ref-
502 The American Journal of Human Genetics Volume 79 September 2006 www.ajhg.org
Table 2. CNV Detection with dChip in
Trios by Use of a Reference Set
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
erence log2 copy-number ratios within each candidate de-
letion or duplication in comparisonwith the ratios outside
the CNV on the same chromosome. The number of SNPs
considered to be part of a CNV varies with the software
and the parameters used to identify the aberrations, so we
tried a range of window sizes (expressed as the number of
contiguous SNPs) around the detected aberration and
computed a t score for every window of the same size on
the chromosome. We tested all reasonable window sizes
for each candidate aberration and deﬁned the optimal
window size as the one that produced the best t score or
equivalent P value for that CNV. Choice of window size
for graphical display of t scores is arbitrary. We chose the
optimal window size with small CNVs to maximize the t
score and to make the aberration more apparent in the
plot. Longer aberrations are generally associated with t
scores that differ greatly from the rest of the chromosome,
and, in these cases, we chose window sizes smaller than
the optimal to produce smoother plots.
Combined Copy-Number and Genotype Analysis
for Deletions
SNP genotype calls were generated from signal intensity
data with GDAS version 3.0 by use of a conﬁdence score
threshold of 0.05 for genotype accuracy. Genotypes were
assessed for each putative deletion identiﬁed by CNAG or
dChip. If the number of heterozygous SNPs exceeded 10%
of the total within a putatively deleted segment, the de-
letion call was considered to be a false-positive result. De-
letions were accepted as hemizygous if at least 90% of the
genotype calls within the segment were either “AA” or
“BB.” Genotype calls within a hemizygous deletion in a
child often exhibited Mendelian errors (e.g., an “AA” ge-
notype result in the child and a “BB” genotype result in
one parent), and such errors were used to determine the
parental origin of the child’s remaining inherited allele.
Copy-Number Analysis of X Chromosomes with dChip
Copy numbers for SNPs on the X chromosome were an-
alyzed with dChip software33 as follows. Each male (child
or father) was compared with a reference set comprising
all 108 unaffected fathers included in the study. Each fe-
male (child or mother) was compared with a reference set
comprising all 108 unaffected mothers included in the
study. Regions of copy-number gain or loss were detected
using the hidden Markov model output of dChip.
Screen for UPD
A search for UPDwas performed using SNP genotypes gen-
erated with GDAS version 3.0, with a conﬁdence score
threshold of 0.05. SNP genotypes for each child were com-
pared with those of both parents, and Mendelian errors
(SNPs homozygous for one allele in the child and the op-
posite allele in one parent) were identiﬁed. Mendelian er-
rors are very infrequent in the absence of deletions or
UPD.When suchMendelian errors were found, other SNPs
within the same chromosomal region or chromosome
were evaluated for the presence of isodisomy or heter-
odisomy. Uniparental isodisomywas identiﬁed as a stretch
of homozygous SNPs in the child with exclusively mater-
nal or exclusively paternal origin. Diagnosis of uniparental
isodisomy also required conﬁrmation of a normal disomic
copy number. Uniparental heterodisomy was detected
when a continuous region within a window of 200–1,000
SNPs in the child showed genotypes identical to the same
chromosomal region in the mother or father.
Validation of CNVs
Putative CNVs identiﬁed by WGSA were validated by FISH
with cytogenetic pellets prepared according to standard
clinical procedures. FISH was performed with BAC or fos-
mid probes selected using the University of California at
Santa Cruz (UCSC) Genome Browser34 and the May 2004
assembly of the human genome sequence.
The genomic content of BAC inserts used for FISH con-
ﬁrmation of putative CNVs was veriﬁed by end sequenc-
ing, as necessary. BACDNAwas prepared as described else-
where,35 was precipitated, and was resuspended in 35 ml
of Ultrapure water (Gibco). DNA sequencing reactions
were assembled in 384-well clear optical reaction plates
(Applied Biosystems) by use of a Biomek FX workstation
(Beckman-Coulter). Each reactionwas performed in a total
volume of 8 ml, consisting of 5 ml of puriﬁed BAC DNA,
0.7 ml of T7 or SP6Wan sequencing primer (5 pmol/ml [In-
vitrogen]), 0.3 ml of Ultrapure water (Gibco), and 2 ml of
BigDye v.3.1 Ready Reaction Mix (Applied Biosystems).
Thermal cycling was performed on a PTC-225 or DNA
Engine Tetrad 2 thermal cycler (MJ Research) with param-
eters of 85 cycles at 96C for 10 s, melting temperature
(which was speciﬁc to each primer) for 5 s, and 60C for
4 min, followed by incubation at 4C. Reaction products
were precipitated by adding 2 ml of 125-mM EDTA (pH
8.0) and 18 ml of 95% ethanol per well, followed by cen-
trifugation at 2,750 g for 30 min in an Eppendorf 5810R
centrifuge. The EDTA/ethanol was immediately decanted,
and reaction products were washed with 30 ml of 70%
ethanol. The 384-well cycle plates were allowed to dry
inverted for 15 min. Samples were resuspended in 10 ml
of Ultrapure water andwere analyzed using a 3730XLDNA
analyzer (Applied Biosystems). The reads were processed,
and their quality was assessed, using Phred.36,37 The end
sequences were aligned with the human genomic se-
quence (May 2004 assembly) by use of BLAT38 via the
UCSC Genome Browser.
BAC or fosmid DNA was isolated by small-scale (mini-
prep) preparation and was labeled with Spectrum Red or
Green (Vysis) by use of a Vysis nick translation reagent
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Figure 2. A CNV on chromosome 2 in the affected child of family
7551. A, dChip-smoothed copy-number (CN) estimate with a win-
dow of 38 SNPs, showing a 1-copy deletion. B, Diagram showing
t scores calculated for a sliding window of 38 SNPs that compare
the copy number estimated by dChip for SNPs within the window
with the copy number estimated for all other SNPs on the same
chromosome. The high (negative) t scores associated with the
deletion indicate that this deviation in copy number is unlikely
to have occurred by chance. In both panels, the X-axis shows the
nucleotide position in Mb.
kit. The labeled product was mixed with 3 mg of human
Cot-1 DNA (Invitrogen) and was isolated by means of a
standard DNA precipitation method. Chromosomes and
nuclei were visualized by counterstaining with 4′,6-di-
amidino-2-phenylindole. For deletions, at least 10 meta-
phase cells were analyzed, and interphase nuclei were ex-
amined but not counted. For duplications, at least 10
metaphase cells and at least 50 interphase nuclei were
analyzed. All FISH probes were tested on metaphase
spreads from unaffected individuals to assure proper hy-
bridization. Of 118 FISH probes successfully tested, 2 hy-
bridized to the wrong location, and 14 produced cross-
hybridization signals.
Results
We performed WGSA with Mapping 100K arrays on
100 children with idiopathic MR and on both parents of
each affected child. We also tested eight unaffected sib-
lings in these families (as negative controls) and eight trios
in which the fetus or child had MR as the result of a
previously recognized chromosomal abnormality (as pos-
itive controls). In this last group, the Mapping 100K ar-
rays demonstrated the expected ﬁndings in all cases,
which included the following known segmental aneu-
somies or UPDs: del(7)(q11.2q11.2), del(11)(p12p14.1),
del(10)(q24.32q25.1), dup(10)(p12.2pter), dup(15)(pter),
UPD 7, UPD 15, UPD 16, and UPD 22.
Data were analyzed to determine copy number along
the length of all chromosomes, and the statistical signif-
icance of variations from the expected copy number was
estimated inwindows of various sizes by t scores calculated
in comparison with the estimated copy number of the
remainder of the chromosome (ﬁg. 2). The ﬁndings for
each child were then compared with those for his or her
parents. Apparent CNVs seen in the child and in at least
one parent were considered likely to be benign polymor-
phisms. Apparent CNVs found in the child but not in
either parent were evaluated by FISH, to conﬁrm the pres-
ence of the CNV and its de novo occurrence. Paternity
was conﬁrmed in all trios studied by use of the SNP ge-
notyping calls produced in the array experiments.
In the course of this study, we identiﬁed a total of 3,125
putative CNVs by WGSA in the 100 studied children with
idiopathic MR. Apparent CNVs were found in all individ-
uals, with a range of 19–43 per child with idiopathic MR.
The median number of apparent CNVs per child was 30
(5th percentilep 22; 95th percentilep 38). Of these var-
iants, 2,669 occurred only once in this data set, and the
majority of false-positive CNV calls is likely to be in this
subgroup. The putative CNVs with the highest statistical
signiﬁcance—that is, those that were least likely to have
occurred by chance alone—were tested by FISH. Of the
3,125 apparent CNVs found in children with MR, 12 were
conﬁrmed both in the child and in one of his or her par-
ents. An example is shown in ﬁgure 3. Some other ap-
parent CNVs correspond to known polymorphisms (Da-
tabase of Genomic Variants), but most are unique and
have not been independently conﬁrmed. All CNVs con-
ﬁdently detected in the eight unaffected siblings of chil-
dren with idiopathic MR were inherited from one of the
parents.
CNVs that were conﬁrmed by FISH in a child with MR
and that were found by FISH to be not present in either
parent were considered to have arisen de novo. We found
such de novo alterations in 11 of the 100 children with
idiopathic MR (table 3). Table 4 summarizes the pheno-
typic abnormalities observed in each of these children.
Eight of the 11 de novo cases had submicroscopic de-
letions that were conﬁrmed by locus-speciﬁc FISH (ﬁgs. 4
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Figure 3. Inherited CNV demonstrated by WGSA with Mapping 100K arrays. A, Plot of t scores for chromosome 2 in father, mother,
and child in family 0674, by use of a 21-SNP window. The SNPs are ordered along the X-axis from pter to qter, with the location shown
in Mb. The child with MR inherited the CNV (blue oval) from his unaffected father. B, FISH conﬁrmation of the inherited CNV on 2q34.
In the father and child, one chromosome 2 (white arrowheads) lacks a signal for probe RP11-93G7, whereas the signal is present on
the other chromosome 2 (red arrowheads). In the mother, the signal for probe RP11-93G7 is seen on both chromosomes 2 (red arrowheads).
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Table 3. De Novo CNVs Detected by WGSA with Mapping 100K Arrays and Conﬁrmed by FISH
Family CNV Type
Chromosome
and Band
Starting SNP
(Locationa in bp)
Ending SNP
(Locationa in bp)
Size of CNV SNP Genotype Summary
OMIM Genes with Abnormal
Phenotypes within CNVbp SNPs
Heterozygous
SNPs in
Informative SNPs
Inherited from
1895 Deletion 13q12.11-
q12.13
rs3929856 (18867056) rs10507342 (24517730) 5,650,674 262 Child, 1; father, 61;
mother, 72
Father, 19; mother, 0 SGCG, GJA3, GJB6, GJB2, and SACS
3476 Deletion 4q21.21-q22.1 rs1493182 (82146749) rs1586340 (93214433) 11,067,684 627 Child, 1; father, 137;
mother, 135
Father, 0; mother, 60 DSPP, PKD2, and SNCA
4794 Duplication 16p13.3 rs1544799 (925718) rs2239318 (3864938) 2,939,220 29 … … GNPTAG, TSC2, CLCN7, IGFALS,
PKD1, ABCA3, MEFV, and CREBBP
4818 Deletion 12q14.2-q15 rs10506536 (63342649) rs10492198 (66780095) 3,437,446 199 Child, 0; father, 15;
mother, 17
Father, 4; mother, 0 GNS
5003 Deletion 2p16.3 rs10490220 (50857428) rs2193411 (51178791) 321,363 25 Child, 0; father, 10;
mother, 2
Father, 0; mother, 2 None
5566 Deletion 14q11.2 rs10483251 (20741117) rs9322978 (20918741) 177,624 5 Child, 0; father, 0;
mother, 0
Father, 0; mother, 0 RPGRIP1
5994b Mosaic trisomy 9 … … … 4,782 … … Many (whole chromosome)
6168 Duplication 17q21.33 rs10514971 (45093545) rs8081154 (46196038) 1,102,493 15 … … SGCA, DLX3, and COL1A1
6545 Deletion 7p22.1-p22.2 rs10499339 (3304850) rs1368052 (6940933) 3,636,083 61 Child, 1; father, 13;
mother, 6
Father, 0; mother, 3 PMS2
7807 Deletion 22q12.1 rs10483135 (26138764) rs6005907 (27552525) 1,413,761 41 Child, 0; father, 10;
mother, 4
Father, 0; mother, 0 CHEK2 and XBP1
8326 Deletion 14q11.2 rs10484227 (19584863) rs10483256 (21207935) 1,623,072 88 Child, 0; father, 36;
mother, 27
Father, 0; mother, 3 NP and RPGRIP1
a Location is given using coordinates from National Center for Biotechology Information assembly 35 of the human genome sequence (June 2004).
b Starting and ending SNPs are not shown because CNV involves the whole chromosome.
Table 4. Summary of Clinical Features in Children with de Novo CNVs Detected by WGSA with Mapping 100K Arrays and Conﬁrmed by FISH
Patient Abnormality Clinical Features Evidence of Pathogenicity
1895 5.7 Mb, del(13)(q12.11q12.13) 6-year-old girl; microcephaly; mild growth retardation; several cafe´-au-lait macules; mild anemia, throm-
bocytopenia, and neutropenia; moderate developmental delay
De novo CNV; large region of genetic
imbalance
3476 11.1 Mb, del(4)(q21.21q22.1) 18-year-old girl; extremely short stature; deep-set eyes with narrow palpebral ﬁssures; low-set, straight
eyebrows; narrow nasal root and bridge; prominent columnella with receding alae nasae, short phil-
trum, and thin, downturned lips; small hands and feet; severe hypotonia; marked pes planus; mild sco-
liosis; severe cognitive impairment
De novo CNV; very large region of genetic
imbalance
4794 2.9 Mb, dup(16)(p13.3) 12-year-old boy; blepharophimosis and ptosis; low-set, mildly dysplastic auricles; mild pectus excavatum;
C5-C6 vertebral fusion; pes cavus and clawed toes; normal growth; full-scale IQ of 46
De novo CNV; gene-rich region; striking simi-
larity to other patients described with cy-
togenetically apparent 16p13 duplication
4818 3.4 Mb, del(12)(q14.2q15) 12-year-old boy; prenatal-onset growth retardation; partial anodontia; mild limitation of extension at el-
bows; mildly short and narrow ﬁngers; tremor; mild developmental delay; osteopoikilosis on radio-
graphic examination
De novo CNV; large region of genetic
imbalance
5003 .32 Mb, del(2)(p16.3p16.3) 7-year-old boy; full-scale IQ of 74; learning problems in both parents; attention deﬁcit disorder; Asper-
ger syndrome; frontal bossing, high anterior hairline, frontal hair whorl, and low posterior hairline;
mild dorsal scoliosis with 13 ribs on left, biﬁd right second rib, hemivertebrae and fusions of T2, T3,
T4, and fusion of L4 and L5; asthma
De novo CNV; no known polymorphic CNVs in
region
5566 .18 Mb, del(14)(q11.2q11.2) 2-year-old girl; large for gestational age at birth, head growth at 97th percentile subsequently, and nor-
mal height and weight; generalized hypotonia and joint hypermobility; short palpebral ﬁssures; mildly
dysplastic auricles; long toes with 2-3 cutaneous syndactyly; developmental delay, especially gross
motor
De novo CNV; no known polymorphic CNVs in
region; deletion lies within that of child
8326 and DECIPHER patient CAM126
5994 Mosaic trisomy 9 (∼20%) 17-mo-old boy; plagiocephaly, torticollis, and broad and prominent forehead with bifrontal narrowing;
low-set ears, small mouth, and short philtrum; puffy hands and feet; undescended testes; hypotonia;
tracheomalacia; enlarged cerebral ventricles; bicuspid aortic valve; moderate-to-severe developmental
delay
De novo CNV; cytogenetic conﬁrmation; phe-
notype characteristic of trisomy 9
mosaicism
6168 1.1 Mb, dup(17)(q21.33) 9-year-old girl; microcephaly; moderate-to-severe conductive hearing loss; bilateral preauricular skin
tags, small ears with abnormal pinnae, and small ear canals; mild retrognathia; mild MR
De novo CNV; large region of genetic
imbalance
6545 3.6 Mb, del(7)(p22.2p22.1) 14-mo-old girl; prenatal-onset growth retardation and microcephaly; patent ductus arteriosus and peri-
membranous ventricular septal defect; failure to thrive; severe developmental delay; brachycephaly, ep-
icanthic folds, midface hypoplasia, and lateral ﬂare of eyebrows; 2-3 syndactyly of toes
De novo CNV; large region of genetic imbal-
ance; DECIPHER case UPP969 has 0.2-Mb
deletion within deleted region of this
patient
7807 1.4 Mb, del(22)(q12.1q12.1) 5-year-old boy; microcephaly; frontal upsweep, hypertrichosis of forehead, and prominent brows; biﬁd
uvula; undescended testes; developmental delay, especially of speech
De novo CNV; large region of genetic imbal-
ance; 1.8-Mb deletion in DECIPHER patient
CHG758 overlaps the CNV in this patient
8326 1.6 Mb, del(14)(q11.2q11.2) 2-year-old boy; small ventricular septal defect that closed spontaneously; large patent ductus arteriosus
that required surgical closure; plagiocephaly; pseudostrabismus with very broad nasal root and short
nose; preauricular pit; undescended testes and hypoplastic scrotum; moderate-to-severe developmental
delay, especially of speech
De novo CNV; DECIPHER patient CAM126 has
similar deletion
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Figure 4. De novo submicroscopic genomic deletion, del(2)(p16.3p16.3), identiﬁed by WGSA with Mapping 100K arrays in family
5003. A, The t scores for the CNV in comparison with the rest of the chromosome, by use of a window size of 20 SNPs. The SNPs are
ordered along the X-axis from pter to qter, with the location shown in Mb. B, FISH conﬁrmation of the CNV in the affected child by
use of probe RP11-1151G3. The white arrowhead indicates the deletion-containing chromosome 2 without the signal. The green arrowhead
indicates the normal homologue, which shows the signal.
Figure 5. De novo submicroscopic genomic deletions identiﬁed
by WGSA with Mapping 100K arrays in the affected child of families
1895, 3476, 4818, 5566, 6545, 7807, and 8326. The legend is
available in its entirety in the online edition of The American
Journal of Human Genetics.
and 5). These CNVs ranged in size from 178 kb (in family
5566) to 111 Mb (in family 3476) and involved 5–627
contiguous SNPs.
Two of the 11 de novo cases had submicroscopic du-
plications that were conﬁrmed by locus-speciﬁc FISH (ﬁgs.
6 and 7). The sizes of these CNVs were 1.1 Mb (15 con-
secutive SNPs) in family 6168 and 2.9 Mb (29 consecutive
SNPs) in family 4794.
We also identiﬁed mosaic trisomy 9 in family 5994. This
abnormality was not detected on initial cytogenetic anal-
ysis but was subsequently conﬁrmed in 1 of 44 cells ex-
amined on an extended cytogenetic survey of peripheral-
blood metaphases and in 60 of 300 peripheral-blood
interphase cells studied by FISH with probes for chro-
mosome 9.
Although we were able to demonstrate the UPD in all
four control cases with known UPD, we did not ﬁnd any
copy-number–neutral alterations of familial genotype pat-
terns indicative of UPD in the 100 studied children with
idiopathic MR. We did not identify any de novo CNVs of
the X chromosome or any inherited regions of X-chro-
mosomal nullisomy in males with idiopathic MR.
Discussion
We have shown that WGSA with Affymetrix Mapping
100K arrays can identify apparently pathogenic, submi-
croscopic CNVs in individuals with idiopathic MR and
normal results of conventional cytogenetic analysis. Our
observed frequency of de novo submicroscopic CNVs is
comparable to that seen in a similarly selected group of
patients with idiopathic MR who were studied using com-
parative genomic hybridization with whole-genome BAC
tiling-path arrays.12 However, using WGSA, we were able
to detect smaller de novo CNVs than those that have been
reported using the BAC tiling-path arrays. In addition, SNP
arrays can identify copy-number–neutral UPD29–31 and can
determine the parent of origin of a child’s remaining allele
in heterozygous deletions, neither of which can be done
by BAC or nonpolymorphic oligonucleotide comparative
genomic hybridization. Although we were able to detect
the UPD in our control samples, we did not ﬁnd UPD in
any of the 100 studied children with idiopathic MR. The
SNP genotypes provided by these mapping arrays were
also useful for conﬁrming paternity within the trios.
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Figure 6. De novo submicroscopic genomic duplication, dup(16)(p13.3p13.3), identiﬁed by WGSA with Mapping 100K arrays in family
4794. A, The t scores for the CNV in comparison with the rest of the chromosome, by use of a window size of 20 SNPs. The SNPs are
ordered along the X-axis from pter to qter, with the location shown in Mb. The de novo CNV is shown inside the blue oval. B, FISH
conﬁrmation of the CNV in the affected child, by use of probe G248P82513E10 in metaphase cells (left) and probe RP11-397B22 in
interphase cells (right). In the metaphase spread, the duplication is indicated by the red arrowhead, and the normal chromosome is
indicated by the blue arrowhead. The signal is duplicated on one chromosome 16.
Figure 7. De novo submicroscopic genomic duplication,
dup(17)(q21.33q21.33), identiﬁed by WGSA with Mapping 100K
arrays in family 6168. The legend is available in its entirety in the
online edition of The American Journal of Human Genetics.
Because of the noise inherent in WGSA with Mapping
100K arrays, statistically signiﬁcant increases or decreases
in apparent copy number often occur by chance. Slater et
al.31 estimated the false-positive copy-number call rate for
WGSA with Mapping 100K arrays to be in the range 2.0%–
3.5%. We employed a different approach for copy-number
analysis and found that the false-positive call rate varied
with the software, parameter settings, and comparison
group. To increase the speciﬁcity of CNV calls, we calcu-
lated t scores for the variation from expected copy number
in the region of interest in comparison with the copy
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Table 5. Ensembl Genes and Fetal Brain
Gene Expression in Regions Deﬁned by de
Novo CNVs in Children with Idiopathic MR
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
number for the rest of a chromosome (ﬁg. 2), and we
accepted only calls that were very unlikely to have oc-
curred by chance alone.
Another advantage of using SNP arrays that provide in-
formation on genotypes as well as copy number is that
some false-positive deletion calls can be recognized by the
presence of heterozygous genotypes within a putatively
deleted region. More generally, the false-positive CNV call
rate can be reduced by requiring a larger number of SNPs
that are adjacent in the genome to demonstrate a similar
apparent gain or loss of copy number, but doing so reduces
the sensitivity and resolution of the analysis. The use of
higher density arrays (e.g., 500K rather than 100K arrays)
and critical assessment of the characteristics that permit
CNVs to be identiﬁed by various software algorithmsmay
help to reduce the false-positive call rate without substan-
tially affecting the sensitivity of the assay.
Affymetrix Mapping 100K arrays have one SNP every
23.6 kb, on average, and an 8.5-kb median distance be-
tween adjacent SNPs, excluding centromeric and telo-
meric regions. We considered a false-positive rate of 4
CNV calls per person to be manageable, given the usual
error proﬁles observed in this study. To obtain this false-
positive rate, we required that at least four adjacent SNPs
exhibit a similar change in apparent copy number to call
a CNV. A larger number of adjacent SNPs was needed to
call a change in copy number when the hybridization
results were unusually noisy.
The smallest conﬁrmed inherited CNV we observed (a
37.6-kb deletion of chromosome 9 in family 9299) ap-
proaches the theoretical resolution of our analytical
method. The smallest conﬁrmed de novo CNV we found
was 178 kb (in family 5566). The fact that we did not ﬁnd
smaller de novo CNVs is unlikely to reﬂect any biological
limit on the minimal CNV size associated with MR.
Smaller pathogenic deletions or duplications have been
found in children with MR by use of other methods.18–23
SNPs included on the Mapping 100K arrays are not
evenly spaced throughout the genome, and somegenomic
regions have denser representation than others. Thus, al-
though we were able to conﬁrm an inherited CNV as small
as 37.6 kb, we may have failed to detect CNVs of several
hundred kilobases if they happen to lie in regions that are
poorly represented on the Mapping 100K arrays. Of par-
ticular concern is the fact that subtelomeric regions and
regions rich in segmental duplications, which are frequent
sites of benign and pathological copy-number varia-
tion,39–41 are poorly represented on these arrays. 500K SNP
arrays have recently become available and should provide
better resolution for WGSA, although subtelomeric re-
gions and regions rich in segmental duplications are still
underrepresented.42
As expected, we found many CNVs that probably rep-
resent normal polymorphisms.43 Our study was not de-
signed to survey these normal variants in detail, and
WGSA may not be the best technology to use for this
purpose.42
We have used the occurrence of a CNV as a new mu-
tation in a child with MR as a screen for pathogenicity of
the variant, because this approach parallels that used clin-
ically to assess cytogenetically apparent chromosomal ab-
normalities. We recognize that some CNVs that are in-
herited from an unaffected parent may nevertheless be
pathogenic—for example, if an inherited deletion uncov-
ers a region that is imprinted or includes a pathogenic
recessive allele on the normal homologous chromo-
some.43,44 We do not know the frequency of de novo CNVs
among unaffected individuals, although we did not ob-
serve any de novo CNVs in the eight unaffected siblings
studied with these trios. We believe that all the de novo
CNVs observed in this study of children withMR are likely
to be pathogenic, because all exhibit features, in addition
to their occurrence as new mutations, that have been as-
sociated with cytogenetically detectable deletions and du-
plications that cause MR.
All 11 de novo CNVs we found in children with MR
contain genes (or portions of genes) annotated by En-
sembl and sequences that are expressed in human fetal
brain (table 5). Almost all these de novoCNVs also contain
genes fromOnlineMendelian Inheritance inMan (OMIM)
that have been associated with phenotypic abnormalities
(table 3), but none of the children has clinical features
compatible with known mutations of these OMIM genes.
The duplication in child 4794 includes a region that is
deleted in some cases of Rubinstein-Taybi syndrome (MIM
180849), a well-characterized multiple congenital anom-
aly MR syndrome.45
The de novo deletions we observed that extend across
11 Mb of genomic sequence (in families 1895, 3476, 4818,
6545, 7807, and 8326) are almost certainly pathogenic,
because of their large size and consequent gene content.
These deletions are similar in size to the pathogenic CNVs
that occur in recognized microdeletion syndromes41 and
are larger than almost all the deletion polymorphisms re-
ported in unaffected individuals.12,39,40,46–51
Two of the de novo deletions we conﬁrmed by FISH are
substantially smaller than the others (321 kb in family
5003 and 178 kb in family 5566), demonstrating the im-
proved resolution of WGSA with Mapping 100K arrays in
comparison with other array hybridization platforms used
to identify CNVs in children with MR.10–17 Despite their
small size, the deletions in families 5003 and 5566 are also
probably pathogenic because, to the best of our knowl-
edge, they have never been observed in unaffected indi-
viduals and because each of these CNVs arose as a new
mutation in the affected child. Similar arguments regard-
ing possible pathogenicity apply to the de novo dupli-
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cations found in this study (ﬁgs. 6 and 7). Both of these
duplications are 11 Mb in size, neither has been reported
in unaffected individuals, and both apparently arose as a
new mutation in the affected child.
The ability of WGSA to detect trisomy 9 mosaicism de-
spite the failure of routine karyotyping to do somay reﬂect
the fact that trisomy 9 cells are selected against under
routine cytogenetic culture conditions or that the trisomy
line happens to be much less frequent in the T-lympho-
cytes that were karyotyped than in other nucleated blood
cells. Our observation that trisomy 9 was conﬁrmed by
FISH in 20% of interphase cells but by cytogenetic analysis
in ∼2% of metaphase cells studied is consistent with both
interpretations.
CNVs frequently occur as benign polymorphisms in
healthy individuals,12,39,40,46–51 and it is not always clear
whether a CNV found in a child with MR is actually path-
ogenic. There are several features that can be used to dif-
ferentiate apparently benign polymorphic variants from
CNVs that may cause MR. Our primary approach was
based on family studies—themethod that is used clinically
to determine whether a novel chromosomal alteration
identiﬁed cytogenetically is pathogenic. In this approach,
a CNV that has been inherited from an unaffected parent
is considered unlikely to be pathogenic, whereas a CNV
that occurs de novo in a child withMR is probably causally
related. Although there are exceptions—for example, in
the case of recessive mutations, imprinted genes, or X-
linked genes transmitted by a woman to her son—family
studies are often very helpful in determining the likeli-
hood that a CNV is pathogenic.
Another useful rule of thumb is that a CNV observed
frequently in unaffected people is unlikely to be patho-
genic in a child with MR. None of the de novo CNVs we
found in affected children is listed in the Database of Ge-
nomic Variants as having been reported in an unaffected
individual, and we did not ﬁnd these changes in any of
the unaffected parents or unaffected sibling controls in
our study.
Some CNVs are known to be pathogenic, because they
have been observed repeatedly in children who share a
particular MR phenotype. The familiar forms of MR as-
sociated with microdeletions of 7q11.23 (Williams-Beuren
syndrome [MIM 194050])52 and 17p11.2 (Smith-Magenis
syndrome [MIM 182290])53 provide cogent examples of
CNVs that were demonstrated to be pathogenic in this
way. Thus, the phenotypic similarity of child 5994 to other
children who have been described with mosaic trisomy
954,55 makes it virtually certain that his MR was caused by
the trisomy 9 mosaicism that we discovered in him by
WGSA.
Five of the other de novo CNVs we found have also been
reported in other children with MR: dup(16)(p13.3p13.3)
in child 4794, del(7)(p22.2p22.1) in child 6545,
del(22)(q12.1q12.1) in child 7807, and del(14)(q11.2q11.2)
in child 8326 and child 5566. The appearance of child
4794 is strikingly similar to that of other individuals with
cytogenetically apparent duplications of 16p13 and es-
pecially to the patient recently described by Sommer et
al.56 The de novo duplication we found in child 4794 also
overlaps that of DECIPHER patient CHG237.
The 1.6-Mb deletion we demonstrated in child 8326 in-
cludes a 1.1-Mb deletion reported in DECIPHER patient
CAM126, and both of these lesions include the 178-kb
deletion that we found in child 5566. These three children
share similar minor anomalies that may constitute a re-
current syndrome. The 3.6-Mb deletion in child 6545 in-
cludes a 0.2-Mb deletion reported in DECIPHER patient
UPP969, and the 1.8-Mb deletion in DECIPHER patient
CHG758 overlaps the 1.4-Mb deletion found in child
7807. A detailed comparison of the phenotypic features
of these individuals is being undertaken.
In a few instances, a CNV found in a child with MR
may include a gene that is known to be dosage sensitive
and to produce the speciﬁc phenotype seen in the child.
This is the case, for example, in children who have neu-
roﬁbromatosis 1 as a result of deletion of the entire NF1
locus.57 When this occurs, the child’s MR may be attrib-
uted to the involved gene, but, even in these instances,
there may be other genes included in the CNV that also
contribute to the MR.
A most compelling demonstration that MR can be
caused by a particular CNV is obtained if sequence mu-
tations of a gene within the affected region produce the
same phenotypic abnormalities as the CNV. This approach
is illustrated by the ﬁnding of CHD7 sequence mutations
in 58% of individuals with CHARGE syndrome (MIM
214800)58 after CHD7 was identiﬁed within the CNVs of
two other children with this phenotype.59 Such investi-
gations have not been performed on the novel CNVs we
found in this study, but the small size of some of these
CNVs makes the genes within them attractive candidates
for mutational analysis in children with MR who do not
have detectable CNVs.
The results of our study demonstrate that WGSA with
high-density, whole-genome SNP arrays can identify ap-
parently pathogenic CNVs as small as 178 kb in children
with MR. This technology appears to be capable of ﬁnding
the cause of MR in at least twice as many affected indi-
viduals as is conventional cytogenetic analysis.
Note Added in Proof.—De novo CNVs were identiﬁed by
50K Xba GeneChip WGSA in 2 of 10 children studiedwho
had multiple congenital anomalies and normal results on
conventional cytogenetic analysis.60
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